{"entity":{"id":"cdmrp-bcrp","kind":"institution","name":"Breast Cancer Research Program (CDMRP)","aka":["BCRP","DoD Breast Cancer Research Program"],"tldr":"The US defense department's breast cancer research fund, set aside by Congress every year since 1992. It has received about 4.5 billion dollars and made more than 7,400 awards, with patients helping decide which research is paid for.","summary":"The programme's stated vision is \"a world without breast cancer\", and its mission is to end breast cancer for service members and their families, veterans and the general public by funding innovative, high-impact research through a partnership of scientists and consumers. Its overarching challenges are to prevent breast cancer, identify determinants of initiation, risk or susceptibility, distinguish deadly from non-deadly breast cancers, conquer overdiagnosis and overtreatment, identify what drives growth and how to stop it, explain why some breast cancers become metastatic, find why and how breast cancer cells lie dormant for years and re-emerge, replace treatment regimens with ones that are more effective and less toxic and improve survival, and eliminate the mortality of metastatic breast cancer.\n\nThe page lists congressional appropriations of $4.521 billion for FY92 to FY25 and $145 million for FY26, and 7,428 awards made in FY92 to FY24. It also lists Breast Cancer Centers of Excellence awards and the Breast Cancer Research Stamp, with $28.8 million received to date.","asOf":"2026-11-04","links":[{"label":"Breast Cancer Research Program","url":"https://cdmrp.health.mil/bcrp/default"},{"label":"BCRP funding history","url":"https://cdmrp.health.mil/bcrp/fundinghistory"}],"tags":["research-funding"],"related":[],"cancers":["breast-cancer","ductal-carcinoma-in-situ"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cdmrp"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-overdiagnosis","b-dormancy-mrd","b-metastasis-biology"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Appropriation totals, award counts and the fiscal-year ranges are the programme page's own figures, read on 4 November 2026; the ranges differ between programmes because each page states its own (some run to FY24, some to FY25), and they are reproduced as given rather than summed or extended.","The stamp figure is the one printed under the Breast Cancer Research Stamp heading; a second figure on the page sits in a block that is not displayed and is left out."],"city":"Fort Detrick, MD","country":"US","lat":39.437,"lng":-77.427,"institutionType":"government","website":"https://cdmrp.health.mil/bcrp/default","programs":["Breakthrough, idea and clinical research awards (by fiscal year announcement)","Breast Cancer Centers of Excellence awards","Breast Cancer Research Stamp funded awards","Consumer reviewers on peer and programmatic panels"]},"route":"/institutions/cdmrp-bcrp/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"ductal-carcinoma-in-situ","kind":"cancer","name":"Ductal carcinoma in situ (DCIS)","route":"/cancers/ductal-carcinoma-in-situ/"}],"institution":[{"id":"cdmrp","kind":"institution","name":"Congressionally Directed Medical Research Programs (CDMRP)","route":"/institutions/cdmrp/"}],"bottleneck":[{"id":"b-dormancy-mrd","kind":"bottleneck","name":"Dormant cells and minimal residual disease","route":"/bottlenecks/b-dormancy-mrd/"},{"id":"b-metastasis-biology","kind":"bottleneck","name":"Metastasis is understood least and studied last","route":"/bottlenecks/b-metastasis-biology/"},{"id":"b-overdiagnosis","kind":"bottleneck","name":"Overdiagnosis and false alarms","route":"/bottlenecks/b-overdiagnosis/"}]}}